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Abstract
Organophosphorus (OP) nerve agents are potent suicide inhibitors of the essential neurotransmitter-regulating enzyme
acetylcholinesterase. Due to their acute toxicity, there is significant interest in developing effective countermeasures to OP
poisoning. Here we impart nerve agent hydrolysis activity into the human drug metabolism enzyme carboxylesterase 1.
Using crystal structures of the target enzyme in complex with nerve agent as a guide, a pair of histidine and glutamic acid
residues were designed proximal to the enzyme’s native catalytic triad. The resultant variant protein demonstrated
significantly increased rates of reactivation following exposure to sarin, soman, and cyclosarin. Importantly, the addition of
these residues did not alter the high affinity binding of nerve agents to this protein. Thus, using two amino acid
substitutions, a novel enzyme was created that efficiently converted a group of hemisubstrates, compounds that can start
but not complete a reaction cycle, into bona fide substrates. Such approaches may lead to novel countermeasures for nerve
agent poisoning.
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Introduction
Organophosphorus (OP) nerve agents are some of the most
poisonous chemicals known (Figure 1A) [1]. By covalently
phosphonylating the catalytic serine of the neurotransmitter-
regulating enzyme acetylcholinesterase (AChE), OPs produce a
cholinergic crisis that can cause respiratory failure and death
[2]. OP nerve agents have been used as chemical weapons
by both established governments and terrorist groups [2,3].
In addition, there are an estimated 250,000 deaths world-
wide each year associated with OP pesticides [4]. Thus, there
is significant interest in developing novel approaches to
detoxify these compounds for military, security and clinical
applications [5].
Human carboxylesterase 1 (hCE1) is primarily expressed in
the liver and metabolizes a variety of chemically distinct
substrates, from potentially harmful endogenous compounds to
exogenous compounds including drugs and environmental toxins
[6]. hCE1 is homologous in structure and catalytic mechanism
to AChE and exhibits features that make it attractive as a
potential nerve agent hydrolase [6]. Both hCE1 and AChE
employ a catalytic triad consisting of serine, histidine, and
glutamic acid residues. In addition, for both enzymes, OP nerve
agents act as hemisubstrates – compounds that can start but not
complete a reaction cycle to regenerate free active enzyme
[7,8,9]. Indeed, hCE1 is potently inhibited by nerve agents,
forming long-lived covalent phosphonyl-enzyme complexes
(Figure 1B) [8]. We have previously shown that hCE1 does
not undergo the dead-end ‘‘aging’’ process from this interme-
diate that is observed for the cholinesterases, AChE or
butyrylcholinesterase (BChE) [10]. In addition, wild-type (wt)
hCE1 exhibits a slow hydrolysis-based reactivation after
exposure to sarin, but no reactivation is observed when hCE1
is exposed to soman or cyclosarin [8].
Thus, we sought to design an hCE1 variant capable of
hydrolyzing OP nerve agents. We employed molecular modeling
techniques based on crystal structures of hCE1 in trapped covalent
complexes with agents to engineer amino acids capable of
promoting dephosphonylation. Herein, we report the placement
of a pair of residues in the hCE1 active site that significantly
increases the rate of nerve agent hydrolysis relative to native
hCE1, while still retaining high affinity and selective functional
substrate activity towards these compounds. Thus, using only two
amino acid changes, we have created one of the most efficient
enzymes engineered to date with respect to converting hemisub-
strates into substrates.
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Structure-Guided Dyad Design
To hydrolyze the covalent phosphonyl-enzyme OP-bound
species of hCE1, we introduced a histidine (H) at position 146
and a glutamic acid (E) at position 363. These residues were
chosen because they appeared ideally positioned to order a water
molecule for hydrolysis. The corresponding wild-type residues
V146 and L363 are positioned on either side of the active site
pocket, adjacent to the OP-serine bond formed during the two-
step catalytic mechanism of the enzyme (Figure 2). V146 is part
of an extended loop between b7 and a2 that also contains the
oxyanion hole formed by residues G142 and G143. L363 caps
a12, at the edge of the hCE1 active site. As outlined below, the
structurally similar residue glutamine (Q) was used as a control
mutation for each position. hCE1 mutants were successfully
expressed, purified, and shown to exhibit enzyme activity using a
standard esterase substrate para-nitrophenylbutyrate (pNPB) [11],
although wildtype hCE1 was ,30-fold faster toward pNPB
than the V146H/L363E mutant (660 nmol/min/mg vs. 21
nmol/min/mg).
Enhanced Nerve Agent Hydrolysis
The V146H/L363E hCE1 mutant exhibited a significant
increase in enzyme reactivation following nerve agent inhibition
(Figure 3A). We had shown previously that wild-type (wt) hCE1
reactivates following sarin exposure at a rate (k3)o f
2.460.50610
24 min
21, or a half-time of reactivation (t1/2)o f
46 hrs, and that wt enzyme was not able to recover following
soman or cyclosarin inhibition [8]. In contrast, however, the
V146H/L363E hCE1 mutant spontaneously reactivated following
sarin and soman inhibition with rates of 1262.0610
24 min
21
(t1/2 of 9.5 hrs) and 1061.0610
24 min
21 (t1/2 of 11.5 hrs),
respectively. The reactivation rates of V146H/L363E hCE1 after
sarin and soman inhibition were 5- and 20-fold faster, respectively,
than the wt enzyme. Most strikingly, the designed V146H/L363E
dyad exhibited a rate of reactivation of 6766.0610
24 min
21 (t1/2
of 1.2 hr) following cyclosarin exposure, an increase in reactivation
of ,33,000-fold relative to wt enzyme (where the wt rate was
estimated to be 1610
25 min
21, the lower limit of rate measure-
ment). Recall that no reactivation was observed with wt hCE1 in
the presence of this OP. Thus, efficient recovery of carboxylester-
ase activity following nerve agent exposure was achieved by
introducing a pair of residues adjacent to the hCE1 active site.
We next tested a series of single and double mutant controls
containing Q residues at positions V146 and L363 to examine the
effect of each mutant on reactivation rate (k3) with respect to sarin,
cyclosarin, and soman hydrolysis (Figure 3B, Table 1). For sarin
hydrolysis, introduction of a polar side chain (H or Q) in either
position alone or in combination produced similar rates of
reactivation, ranging from 3.2610
24 to 26610
24 min
21,u pt o
a 11-fold increase relative to wt hCE1. Following soman or
cyclosarin inhibition, L363E appeared critical to increasing k3
from sub-detection limits in wt hCE1 to 4.0610
24 and
19610
24 min
21, up 8- and 9,300-fold, respectively (Table 1).
For soman, polar residues at position 146 (H or Q) weakly
stimulated reactivation; however, when V146H was combined
with L363E, reactivation increased 20-fold relative to wt hCE1
(Table 1).
However, the largest k3 enhancement was for cyclosarin and the
V146H/L363E mutant. This designed enzyme exhibited an
increased rate of enzyme-mediated cyclosarin dephosphonylation
of .33,000-fold relative to the wt enzyme (Table 1). A second
double-mutant in which a Q at position 146 was combined with an
E at position 363 was also found to exhibit robust enzyme
reactivation following cyclosarin exposure, with an rate increase of
Figure 1. Organophosphate (OP) inhibition of human carboxylesterase 1 (hCE1). A. Three G-type OP nerve agents and OP model
compound (R represents respective O-alkoxy groups). Wild-type hCE1 preferentially binds the stereoisomers shown (7). B. Schematic mechanism of
OP hydrolysis by hCE1. X represents the leaving group and * denotes a non-reactive state.
doi:10.1371/journal.pone.0017441.g001
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acid at position 363 appeared to function as a catalytic base to
enhance cyclosarin reactivation; a glutamine in that position failed
to stimulate enzyme activity in the presence of cyclosarin. Taken
together, these data demonstrate that targeted mutagenesis within
hCE1 can significantly increase nerve agent processing by this
serine hydrolase.
Structural Mechanism for Enhanced Cyclosarin Hydrolysis
The crystal structure of hCE1 in covalent complex with
cyclosarin was then used to generate an energy-minimized model
of V146H/L363E hCE1. In the resultant model, the side chains of
L363E and V146H were found to be 3.3 A ˚ apart. In addition, the
orientation of L363E suggested that a water molecule could be
positioned 3.2 A ˚ from L363E and 3.2 A ˚ from the phosphorous
atom on the OP-enzyme adduct (Figure 4A). Based on this model
and the biochemical data presented above, we propose that L363E
is positioned for water activation and is stabilized by H146
(Figure 4B). Indeed, pH rate dependence studies showed that
reactivation proceeded most effectively below pH 6.2, when
V146H is likely to be positively charged (Figure 4C).
Bimolecular Rates of Inhibition
To ensure that the enhanced rates of reactivation of V146H/
L363E were not artifacts of altered substrate binding, we
determined the bimolecular rates of inhibition (ki) of the mutant
protein with racemic cyclosarin or stereoisomers of OP model
compounds similar in structure to cyclosarin, and compared those
rates to wt enzyme. V146H/L363E hCE1 exhibited a similar ki to
wt hCE1, confirming that the ability of the mutant protein to bind
cyclosarin and related OP compounds was not disrupted (Table 2,
Table 3). Indeed, as measured with stereoisomers of the model
compounds, V146H/L363E exhibited an improved binding
constant (Km) compared to wt hCE1 with either stereospecific
compound [8]. Therefore, the addition of an ion pair across the
active site entrance was not detrimental to cyclosarin binding.
Discussion
OP nerve agents serve as hemisubstrates of the wild-type AChE,
BChE, and hCE1 enzymes because these chemicals fail to
complete the typical two-step serine hydrolase mechanism.
Rather, OP nerve agents produce relatively long-lived covalently
phosphonylated active site serines [12,13]. Histidine (H468 in wt
hCE1; see Figure 2B) activates the serine (S221 in hCE1) for
nucleophilic attack on the OP phosphonyl center. The resultant
pentahedral intermediate is stabilized by hCE1 backbone nitrogen
atoms in the oxyanion hole (G142 and G143); the fluoride leaving
group dissociates upon collapse of the transition state, resulting in
a covalently modified enzyme [14]. The resulting tetrahedral
phosphonyl adduct adversely affects the ability of H468 to
facilitate base mediated C-O bond cleavage [15], which leaves
this residue in a state where it cannot activate the water molecule
required for hydrolytic desphosphonylation [16]. Thus, for serine
hydrolases like AChE and hCE1 that are inhibited by OP
hemisubstrates, the addition of a strong oxime is often required to
complete the catalytic cycle and regenerate active enzyme.
Current treatments following OP exposure include administration
of strongly-nucleophilic oximes to dephosphonylate AChE.
However, such compounds, such as 2-pralidoxime obidoxime,
Figure 2. Human carboxylesterase 1 active site structure. Active site of human carboxylesterase 1 covalently inhibited via S221 with cyclosarin
(magenta) [8]. The other catalytic residues, in addition to S221, are H468 and E354 (yellow), and are surrounded by hydrophobic residues (grey
surface) including V146 and L363 (light blue), as well as the oxyanion hole (white).
doi:10.1371/journal.pone.0017441.g002
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be administered quickly [17].
Based on previous crystal structures of hCE1 in covalent
complexes with nerve agents [7,8], we hypothesized that
introducing a general base catalyst would facilitate the activation
of a properly located water molecule to hydrolyze an OP adduct.
The V146H/L363E amino acid substitutions dramatically in-
creased the spontaneous rates of enzyme reactivation following
sarin, soman, and cyclosarin inhibition compared to native
enzyme (Figure 3). A panel of single and double mutant controls
indicated that V146H or L363Q facilitated increased sarin
hydrolysis, while L363E acted as general base catalyst for
cyclosarin and soman hydrolysis. Because V146H, L363Q, or
their combination, resulted in similar rates of reactivation, these
mutations may enhance dephosphonylation by interacting with
the sarin O-isopropyl group, thereby affording deprotonation of
Figure 3. Reactivation of hCE1 following nerve agent exposure. A. Spontaneous reactivation of V146H/L363E hCE1 following inhibition by
racemic sarin (blue), soman (green), or cyclosarin (red). Wild type hCE1 (grey) only reactivates following sarin inhibition (7). n=6, s.d. B. Rates of
dephosphonylation for hCE1 variants in the presence of sarin (blue), soman (green) and cyclosarin (red). n=3, s.d.
doi:10.1371/journal.pone.0017441.g003
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hCE1 Sarin Soman Cyclosarin
k3 (610
24 min
21) Fold Increase k3 (610
24 min
21) Fold Increase k3 (610
24 min
21) Fold Increase*
WT 2.460.5 - 0.560.3 - ,0.01 -
V146H 20648 2 61 4 0.03260.006 16
V146Q 3.260.9 1 261 4 0.3460.09 171
L363E 4.660.5 2 4618 1 9 65 9,300
L363Q 14616 ,0.01 - ,0.01 -
V146Q/L363E 5.760.7 2 2.660.5 5 4367 21,500
V146H/L363Q 26631 1 ,0.01 - ,0.01 -
V146Q/L363Q 12615 ,0.01 - ,0.01 -
V146H/L363E 12625 1 0 612 0 6 7 66 33,355
N.R. is no reactivation with a detection limit ,1610
25 min
21.
pH 7.4, 25uC, N=3, s.d.
*k3,1610
27 min
21, i.e. (1610
25 min
21)*(1% activity)/100.
doi:10.1371/journal.pone.0017441.t001
Figure 4. Mechanism of reactivation by V146H/L363E hCE1 after cyclosarin binding. A. Model of V146H/L363E (cyan) hCE1 with PR
cyclosarin (magenta) including a water molecule (red) between E363 and the central phosphorus. B. Proposed mechanism for enhanced reactivation
following cyclosarin inhibition. C. pH dependence of V146H/L363E (black) and L363E (grey) hCE1 dephosphonylation following cyclosarin inhibition.
doi:10.1371/journal.pone.0017441.g004
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mutation in BChE resulted in increased rates of dephosphonyla-
tion through an analogous mechanism [16,18].
In contrast, the L363E mutation positions an anionic carbox-
ylate adjacent to the phosphonyl-enzyme intermediate to activate
a water molecule for nucleophilic attack. Glutamic acid and
aspartic acid residues act as general acid-base catalysts in several
established enzyme mechanisms, including those of lysozyme and
protein tyrosine phosphatases [19,20], and apparently support the
same role in hCE1. The V146H addition synergistically increased
base activity of L363E (Figure 4A). The pH profile for cyclosarin
hydrolysis by V146H/L363E showed that the fastest rates of hCE1
reactivation was when H146 was likely to be in a charged state,
below pH 6.2 and where a cationic H146 can stabilize the anionic
base (Figure 4C). Based on these data, we postulate that E363
Oe1 is stabilized by H146 and Oe2 on E363 is available to
deprotonate a water molecule to hydrolyze the covalent cyclohexyl
phosphonyl group (Figure 4B). This hypothesis is supported by
the observation that the V146Q/L363E variant also exhibited a
significant increase in cyclosarin hydrolysis (Table 1).
Previous attempts to introduce general base catalysts in OP-
inhibited serine hydrolases have resulted in enzymes that also
showed enhanced rates of reactivations against soman, sarin, and
VX, but the ability of these mutant enzymes to bind the respective
OPs was greatly diminished [10,16]. For example a G117H/
E197Q BChE mutant enhanced the rate of soman hydrolysis up to
2,500-fold faster than wt BChE, but the soman bimolecular rate of
inhibition for this mutant was decreased by a similar magnitude
[10]. In contrast to the G117H/E197Q BChE mutant, V146H/
L363E hCE1 exhibits a greater second-order rate of inhibition (ki)
than the wt hCE1 enzyme (Table 2). Further, the Km values for the
cyclosarin model compounds reported in Table 2 demonstrate that
the affinity for V146H/L363E hCE1 is greater than the wt enzyme
for these analogs. Taken together, these data show that V146H/
L363E hCE1 retains greater than wt affinity for cyclosarin, and that
the engineered hCE1 mutants enhance rates of reactivation via
dephosphonylation rather than decreasing inhibition.
In conclusion, we have rationally designed a variant form of the
liver detoxifying enzyme hCE1 that spontaneously dephosphony-
lates after inhibition by sarin, soman, and cyclosarin up to 33,000-
fold faster than wt enzyme. Wild type hCE1 has a catalytic
efficiency (kcat/Km) [21] towards the standard esterase substrate
para-nitrophenylbutyrate (pNPB) of 1.2610
5 M
21s
21 [22].
AChE, one of the most efficient enzymes known, exhibits a kcat/
Km close to the diffusion control limit (10
8 M
21s
21) for
acetylcholine hydrolysis [23]. Combining the nanomolar Km of
V146H/L363E towards the PR cyclosarin-like compound along
with rate of reactivation after inhibition by this compound, this
double mutant shows a catalytic efficiency of 8.8610
2 M
21s
21.
Thus, the redesigned hCE1 compares favorably to other
mammalian enzymes that have been rationally engineered to
improve hemi-substrate metabolism (Table 4). This enzyme will
likely require substantial increases in catalytic efficiency for OP
compounds in order to provide in vivo protection, but nonetheless
can serve as a lead candidate for further development of novel
countermeasures for nerve agent or pesticide poisoning.
Materials and Methods
hCE1 Mutagenesis, Expression, and Purification
Site-directed mutagenesis was done using PCR to introduce the
desired amino acid changes into hCE1 (Genbank accession
M73499). Briefly, 100 pM of both sense and anti-sense primers
were mixed with 50 ng hCE1 cDNA in a pUC9 vector, 200 mM
dNTPs, 16 Pfu-BSA buffer, and 2 u Pfu (New England Biolabs,
Ipswich, MA). Mutations were produced through 15 cycles of
PCR, where each cycle consisted of 95uC for 1 minute, 58uC for
30 seconds, and 70 C for 10 minutes. The reaction was digested
for 1 hour with Dpn1 (Fermentas, Burlington, Ontario) at 37uC
and transformed into chemically competent DH5a cells (Invitro-
gen, Carlsbad, California). pUC9 plasmids were isolated with a
GeneJET Plasmid Miniprep kit (Fermentas) and mutations were
confirmed by DNA sequencing. Once the mutations were
Table 2. Bimolecular rates of inhibition, Michaelis-Menten
constants, and rates of reactivation for wild-type and V146H/
L363E hCE1 against racemic cyclosarin and stereoisomers of
cyclosarin model compounds.
V146H/L363E ki (610
3 M
21s
21) Km (610
26 M) k3 (610
24 min
21)
Racemic
a 7962 N.D. 6766
PR
b 5.460.4 0.09560.006 50610
PS
b 0.1260.02 5.260.7 40610
WT
Racemic
a 1165 N.D. ,0.01
c
PR
b 1561
c 0.3260.01
c ,0.01
c
PS
b 0.005360.0007
c 17006200
c ,0.01
c
N=3, s.d., N.D. is not determined, N.R. is no reactivation, pH 7.4, 25uC.
aRacemic bona fide cyclosarin,
bstereoisomers of cyclosarin model compounds,
c(8).
doi:10.1371/journal.pone.0017441.t002
Table 3. Inhibition and Michaelis-Menten constants for wild-type and V146H/L363E hCE1 against stereoisomers of sarin and
soman model compounds.
hCE1 Model Compound ki (610
3 M
21s
21) Km (610
26 M)
PR PS PR PS
WT
a Sarin 0.7760.05 4.160.1 1.460.2 0.3760.02
Soman 2.560.5 0.001560.0007 0.2260.02 8006200
V146H/L363E Sarin 3.4060.07 4.760.2 3.560.8 0.960.1
Soman 10.860.4 0.6760.06 0.10160.005 862
(N=3, s.d.)
a(7).
doi:10.1371/journal.pone.0017441.t003
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pCIneo for mammalian cell expression (Promega, Madison, WI).
Non-secreted forms of wt and mutant hCE1 proteins were
expressed in COS-7 cells (American Type Culture Collection,
Rockville, Maryland) as previously described [11]. Presence of
active hCE1 was determined by measuring the rate of nitrophenol
production in the presence of 3 mM o-nitrophenol acetate through
a change in absorbance at 420 nm. Specific activities were
determined by normalizing hCE1 activity relative to protein
expression as visualized through western blot analysis with an anti-
hCE1 antibody [11]. To facilitate measurement of additional
kinetic constants, secreted forms of wt and V146H/L363E hCE1
were expressed in Spodoptera frugiperda Sf21 insect cells (Clontech,
Palo Alto, California) using baculovirus-expression vectors and
purified as previously described [24].
Examination of Kinetics of hCE1 Variants
Experiments with all racemic OP nerve agents were conducted
at the United States Army Medical Research Institute of Chemical
Defense (USAMRICD), Aberdeen Proving Ground, MD. Nerve
agents were obtained from the U.S. Army Edgewood Chemical
Biological Center (ECBC, Aberdeen Proving Ground, MD).
Analysis by nuclear magnetic resonance spectroscopy showed
them to be .95% pure. Dilute nerve agent was handled according
to safety guidelines in place at USAMRICD. All kinetic assays
were conducted at 25uC. In separate experiments, 50 mL of whole
cell COS lysates expressing an hCE1 mutant was inhibited with a
,1000-fold molar excess of racemic sarin, soman, or cyclosarin for
10 minutes. Unbound agent was removed by passing inhibited
samples over a CENTRI-SEP size exclusion column (Princeton
Separations, Adelphia, NJ). The column eluate was diluted 10-fold
in 0.1 M potassium phosphate buffer, pH 7.4. Aliquots were tested
for hCE1 carboxylesterase functional activity using 5 mM pNPB
and compared to an uninhibited sample. Measurements were
taken over 60 hours, and the observed rate of enzyme reactiviation
(kobs), or the ability of enzyme to hydrolyze pNPB, and maximal
percent recovery (Amax) were determined by fitting the collected
data to equation 1:
A~AOzAmax 1{e{kobst 
ð1Þ
where A was the percent activity at time t, and A0 was the initial
activity at t=0. Reactivation experiments were conducted in
triplicate and independently replicated. It should be noted that
these experiments gauge reactivation via a second substrate and do
not measure OP turnover or its products directly.
Phosphonylated esterases may either spontaneously reactivate
or reside in an inactive state, which is the aged state [8]. However,
for wt hCE1 no aging has ever been measured. As shown in
Figure 1B these two pathways compete as first-order reactions.
Therefore, the true rate of enzyme dephosphonylation (k3) was
determined by equation 2 [25]:
k3~ Amax ðÞ kobs ðÞ =100 ð2Þ
where kobs and Amax were defined in eq. 1. The denominator
normalizes for Amax. All data were analyzed in KaleidaGraph 4
(Synergy Software, Reading, PA). Because the reactivation step
represented by k3 was the slow step in the OP hydrolysis reaction,
k3 effectively represented the rate of OP turnover.
To determine the bimolecular rate of inhibition (ki) with racemic
cyclosarin, 100 nM of purified V146H/L363E hCE1 or wt
enzyme was exposed to 100-fold excess of cyclosarin and the
decrease in pNPB hydrolysis was measured over time. Data were
fit to equation 3 and the ki was calculated by dividing the rate of
phosphonylation (k2) by the cyclosarin concentration:
A~AOek2t ð3Þ
where A is the CE activity at a given time t, and A0 is the enzyme
activity prior to cyclosarin inhibition.
Further inhibition kinetics were determined with stereoisomers
of OP model compounds, where 100 nM of V146H/L363E hCE1
was incubated at room temperature with increasing concentrations
of inhibitor. The thiomethylated OPs examined (Figure 1A) have
previously been shown to form identical adducts to bona fide nerve
agents [8,13]. These compounds were generously provided by Dr.
John Cashman at the Human BioMolecular Research Institute
and their synthesis is described by Gilley et al. [13]. Aliquots of
enzyme in the presence of sarin, soman, and cyclosarin model
compounds were removed at various time points (up to 1 hour)
and the level of remaining enzyme activity was determined by
comparing 4-methylumbelliferyl acetate (4-MUA) hydrolysis
relative to an uninhibited sample. 4-Methylumbelliferone fluores-
cence emission, measured at 450 nm following excitation at
350 nm, was monitored at 37uC on a Pherastar microplate reader
(BMG Labtech, Cary, NC) and the data were fit to equation 4
[26]:
Dt
Dlnv
~
Km
k2
|
1
OP ½  1{a ðÞ
z
1
k2
ð4Þ
Table 4. Catalytic efficiencies (kcat/Km) of engineered enzymes towards hemisubstrates.
Enzyme Engineered Activity Mutation(s) Catalytic Efficiency (M
21s
21)
Butyrylcholinesterase Sarin hydrolysis
a G117H 0.79
Glutathione Transferase A1-1 Thioester hydrolysis
b A216H 2.60
4-Oxalocrotonate Tautomerase Oxaloacetate decarboxylase
c P1A 114
Phospho(serine/threonine/tyrosine)
Binding Protein
Phosphatase activity
c G120C 490
Human Carboxylesterase 1 Cyclosarin analog hydrolysis V146H/L363E 877
Cyclophilin Protease activity
c A91S/F104H/N106D 1675
a(16).
b(32).
c(32).
doi:10.1371/journal.pone.0017441.t004
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k2 the unimolecular phosphonylation rate constant, v the
remaining percent enzyme activity, and [OP] the OP concentra-
tion. The term a was defined as [S]/(Km+[S]), in which [S] was the
substrate concentration and Km was the 4-MUA Michaelis-
Menten constant. For these experiments a was 0.91. All
experiments were performed in triplicate and data were analyzed
to determine ki, where ki=k2/Km [16]. Again, all data were
analyzed in KaleidaGraph 4.
Computational Modeling of hCE1 Mutants
To simulate the hCE1-OP crystal structure for computational
design, a new residue type was created for S221 covalently
inhibited by sarin, soman, or cyclosarin. Following removal of all
water molecules, saccharides, ligands, and extra monomers from
the hCE1-cyclosarin homotrimer crystal structure (RSCB PDB
3K9B [8]), protein hydrogen atoms were added into one monomer
with Molprobity [27]. OP-inhibited S221 hydrogen atoms were
added using Accelrys Discovery Studio Visualizer 2.5 (Accelrys,
San Diego, CA). Any strain or steric interactions in the resulting
structure were then removed by performing 50 steps of conjugate
gradient energy minimization.
Residues with side chains pointing towards and within 5 A ˚ of
the OP, V146, or L363 residues (using 3K9B numbering, residues
89, 90, 93, 96, 97, 100, 101, 145, 220, 222, 252, 254, 255, 304,
318, 358, 359, 361, 364, 388, 425, 426, and 468,) were allowed to
sample alternative conformations during the design phase of the
simulation, but their identities were not modified. At positions 146
and 363, only histidine or glutamic acid was allowed, respectively.
A standard backbone-dependent side chain rotamer library with
expansions by one standard deviation about x1 and x2 was used
[28]. The crystallographic conformer at each designed position
was also allowed. Prior to the modeling procedure, rotamer
libraries for the various OPs were generated. The OP rotamer
libraries introduced torsions in the phosphorus-alkoxy oxygen and
alkoxy oxygen-carbon bonds of each OP-bound serine residue, in
5u increments. The rotamers with conformational energies lower
than a specified value (usually 0) were included in the OP rotamer
library. Computational design was done using the PHOENIX
protein design software. The energy function used was based on
the DREIDING force field [29] and included a scaled van der
Waals term, hydrogen bonding and electrostatic terms, as well as
terms for implicit solvation and phi-psi propensities [29]. Implicit
solvation energies were evaluated using a model based on
occluded volume. Amino acid phi-psi propensities were derived
and applied following the method of Shortle [30]. The final model
consisted of the lowest energy rotamers for the OP, V146H,
L363E, and surrounding active site residues.
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